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Abstract 9 
Non-communicable diseases (NCDs) such as cardiovascular disease, diabetes and 10 
cancer were responsible for 68% of all deaths worldwide in 2012. The regional distribution of 11 
lipid deposited within adipose tissue (AT) - so called body fat distribution (BFD) - is a strong risk 12 
factor for NCDs. BFD is highly heritable; however, the genetic basis of BFD is almost entirely 13 
unknown. Genome-wide association studies have identified several loci associated with BFD, 14 
including at Plexin D1 (PLXND1) - a gene known to modulate angiogenesis. We recently 15 
demonstrated that zebrafish homozygous for a null mutation in plxnd1 had a reduced capacity 16 
to store lipid in visceral AT (VAT) leading to altered BFD. Moreover, we found that type V 17 
collagens were upregulated in plxnd1 mutants, and mediated the inhibitory effect of Plxnd1 on 18 
VAT growth. These results strengthen evidence that Plxnd1 influences BFD in human 19 
populations, and validate zebrafish as a model to study BFD.  However, many pertinent 20 
questions remain unanswered.  Here we outline potential Plxnd1 mechanisms of action in AT, 21 
and describe the genetic architecture at human PLXND1 that is associated with BFD and NCD 22 
susceptibility.  23 
 24 
Commentary 25 
Adipose tissues (ATs) regulate energy homeostasis by supplying and sequestering 26 
energy-dense lipid in response to fluctuations in energy status. As such, AT provides an 27 
organism with energetic stability [1]. Evolutionarily, the energy insurance provided by AT confers 28 
tremendous selective advantages for a population when confronted with diverse physiological 29 
burdens. However, in modern societies - when energy-dense food is readily available, food 30 
consumption is high and physical activity is low - excessive lipid deposition within AT can lead 31 
to AT dysfunction and systemic metabolic disturbance increasing risk for non-communicable 32 
diseases (NCDs) such as cardiovascular disease, diabetes and cancer. In 2012, NCDs 33 
accounted for 68% of all deaths worldwide [2, 3]. Of the 52.8 million deaths globally in 2010, 34 
ischemic heart disease and stroke collectively killed 12.9 million (24% of all deaths), 1.3 million 35 
deaths were caused by diabetes (2.5%) and 8 million died from cancer (15%). Therefore, 36 
understanding factors that influence or predict NCD risk is an important public health challenge.  37 
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ATs are highly heterogeneous and deposited in diverse regional locations throughout the 38 
body. Regionally distinct ATs have unique molecular and metabolic attributes that influence 39 
whole-animal physiology. Accumulation of AT in the upper body (an android BFD) is associated 40 
with increased risk for NCDs [4]. Whereas accumulation of AT in the lower body, primarily the 41 
legs and thighs (a gynoid BFD) protects from NCD risk [4]. Android BFD is characterized by 42 
increases in visceral AT (VAT, AT within the abdominal cavity) and abdominal subcutaneous AT 43 
(SAT, AT between skin and muscle), whilst gynoid BFD is characterized by increased gluteal 44 
and femoral SAT [4].  Understanding factors that regulate the diverse patterns of BFD within 45 
human populations is likely to provide important new therapeutic interventions for NCDs. 46 
Heritability estimates from twin studies suggest that BFD is under extensive genetic 47 
control [5, 6]. However, the genetic basis of BFD is essentially unknown. Recently, the Genetic 48 
Investigation of ANthropometric Traits (GIANT) consortium performed large-scale meta-49 
analyses of genome-wide association studies (GWAS) to identify loci associated with waist-hip 50 
ratio (WHR) – a surrogate measure of android and gynoid patterns of BFD [7, 8]. Intriguingly, 51 
GWAS have found WHR-associated loci are independent from more generalized adiposity traits, 52 
suggesting that a distinct genetic architecture underlies BFD [9]. GWAS provide an unbiased 53 
and comprehensive assessment of genetic loci associated with WHR. However, functional 54 
characterization of GWAS loci is essential to identify mechanisms influencing BFD and disease 55 
susceptibility.  56 
The rs10804591 single nucleotide polymorphism (SNP) identified in Shungin et al. (2015) 57 
encodes a C  A base change, at 3q22.1 ~8kb upstream of the PLXND1 transcriptional start 58 
site (Fig. 1) [7]. The rs10804591 A allele (effect allele, EA) was associated with increased 59 
WHRadjBMI (WHR adjusted for BMI) (P = 2.31 x 10-6), increased susceptibility to type 2 diabetes 60 
(P = 1.67 x 10-3), increased fasting glucose (P = 0.048), increased fasting insulin (P = 6.08 x 10-61 
3), increased blood triglycerides (P = 9.37 x 10-4), decreased Adiponectin (P = 7.81 x 10-3), 62 
increased risk for coronary artery disease (P = 0.018) and decreased height (P = 2.53 x 10-5). 63 
Similar to many of the BFD-associated SNPs, rs10804591 demonstrated a high degree of sexual 64 
dimorphism – often exerting a stronger effect in women (Fig. 2) [7]. Further, the effect in males 65 
and females appeared different, with males also exhibiting reductions in both waist and hip 66 
circumferences (Fig. 2) [7]. Gender differences in adiposity are well known, with females having 67 
a higher body fat percentage, and greater gluteal-femoral AT relative to males [10]. BFD is 68 
regulated by sex hormones, as evidenced by redistribution of AT towards an android distribution 69 
following menopause [11, 12]. rs10804591 EA is common, present at a frequency of 28%, 65%, 70 
28%, 78% within African, American, East Asian, and European populations respectively (1000G 71 
Phase 1, a 51% frequency in all individuals). Intriguingly, rs10804591 is located within a 72 
predicted promoter flank region 5’ of PLXND1 (asterisk in Fig. 1), suggesting that rs10804591 73 
might regulate PLXND1 expression. However, the mechanism of rs10804591 action is 74 
completely unknown. Importantly, within individuals of European ancestry, rs10804591 is also 75 
linked to 41 other common SNPs clustered 5’ to PLXND1 (>0.7 R2 linkage disequilibrium) (Fig. 76 
1), and many of these linked SNPs also reside in predicted regulatory regions (Fig. 1). Searching 77 
the Genotype-Tissue Expression (GTEx) Project revealed that the majority of the 41 SNPs at 78 
PLXND1 were associated with PLXND1 mRNA changes in whole blood (N = 338). No 79 
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associations were found with expression changes in VAT (N = 185); however, this is potentially 80 
due to lower sample size. The investigation of functional variants at PLXND1 is likely to provide 81 
exciting new insights into the genetic underpinnings of BFD. 82 
PLXND1 is a multipass transmembrane receptor for a variety of Semaphorin (SEMA) 83 
ligands, including SEMA3E [13, 14] and SEMA4A [15]. Binding of SEMA3E/4A to PLXND1 84 
suppresses angiogenesis - the process of new blood vessel formation from existing vessels [13-85 
15], and mutation of Plxnd1 in mouse and zebrafish causes hypervascularization of multiple 86 
tissues [16, 17].  Therefore, PLXND1 is a potent anti-angiogenic molecule. The role of 87 
angiogenesis is of particular relevance to AT biology as angiogenesis is known to regulate lipid 88 
accumulation in AT [18-20], and stimulation of angiogenesis specifically in AT can normalize 89 
metabolic disturbances present in obesity [20, 21]. Furthermore, depot-specific angiogenesis 90 
has been linked to systemic insulin resistance – a precursor to diabetes [22], suggesting that 91 
depot-specific differences in angiogenesis may underlie regional AT expansion and NCD 92 
progression. Further, we found that PLXND1 mRNA was positively associated with hypertrophic 93 
morphology in VAT, and was increased in obese type 2 diabetics relative to lean and healthy 94 
obese subjects [23]. 95 
Prior to analysis of human PLXND1, we turned to zebrafish as a tractable in vivo model 96 
system to functionally evaluate the role of PlxnD1 on BFD. Zebrafish possess AT that is 97 
morphologically, molecularly, and functionally homologous to mammalian white AT [23-30]. 98 
Further the molecular mechanisms governing AT dynamics seems conserved from zebrafish to 99 
mammals, as suggested by modulators of nuclear receptors exerting similar effects [31].  100 
Fluorescent lipophilic dyes such as Nile Red and BODIPY can be utilized to visualize and 101 
quantify regional AT in live zebrafish (Fig. 3). Analysis of zebrafish homozygous for the 102 
functionally null plxnd1 allele, fov01b, revealed an altered BFD, characterized by reduced VAT 103 
[23] (both pancreatic and abdominal VAT deposits) [30]. On closer inspection we found plxnd1 104 
mutant VAT was in a hyperplastic and hyperproliferative state, with an induction of type V 105 
collagens in vascular endothelial cells and altered extracellular matrix (ECM) composition [23]. 106 
Maintenance of the hyperplastic/hyperproliferative state was dependent on collagen type V 107 
alpha 1 (col5a1) and conferred resistance to VAT expansion coupled with improved glucose 108 
tolerance after exposure to a high-fat diet [23]. These data suggest that the ECM 109 
microenvironment can determine the proliferative capacity and growth of VAT, and that vascular 110 
endothelial cell-derived Plxnd1 modulates the VAT ECM microenvironment in part through 111 
Col5a1 (Fig. 4A). Regarding this mechanism, here we discuss a potential Integrin-mediated 112 
pathway by which PlxnD1 may regulate ECM composition.  113 
Integrins are heterodimeric collagen receptors that mediate cross-talk between the cell 114 
cytoplasm and extracellular ECM [32]. The Integrin family of genes is comprised of 18 distinct α 115 
subunits and 8 β subunits, which can dimerize to produce 24 heterodimeric combinations (the 116 
Integrin code). Integrin expression can be regulated transcriptionally [33-37], post-117 
transcriptionally by miRNAs [38], and also at the post-translational level. For example, Integrins 118 
can form an inactive ‘closed confirmation’ with low affinity for extracellular ligands, or an active 119 
‘open confirmation’ with high affinity for ligands. Regulation of these states has been well studied, 120 
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with multiple regulators identified (e.g., SHARPIN and SHANK) [39, 40]. Although how this form 121 
of Integrin regulation impacts adipose tissue is currently unknown. Intriguingly, the metabolic 122 
sensor, AMP-activated protein kinase (AMPK), was recently also identified as a regulator of β1 123 
Integrin activity [41]. However, a role for AMPK in regulating adipose ECM and growth is also 124 
unknown. Distinct Integrin heterodimers possess different ECM-binding potentials [42], and 125 
regulate ECM abundance and composition by modulating collagen synthesis and turnover [43, 126 
44]. Therefore, we hypothesize that PlxnD1 modulates the collagen composition of VAT by 127 
regulating the Integrin code displayed on the vascular endothelial cell-surface. It is known that 128 
Integrin expression changes during adipocyte differentiation [45], and that overexpression of 129 
Integrin α5 in preadipocytes leads to enhanced proliferation and attenuated differentiation [45]. 130 
GTPases hydrolyze guanosine triphosphate (GTP), and the GTPase, Rac, is normally 131 
downregulated during adipocyte differentiation [45]. Overexpression of Integrin α5 increases 132 
Rac activity, suggesting that GTPase levels are critical for preadipocyte proliferation and 133 
differentiation [45, 46]. In support, Focal Adhesion Kinase (FAK) plays a central role in Integrin 134 
signaling and is essential for adipose expansion [47, 48]. GTPases control many cell functions, 135 
including deposition and maintenance of Integrins on the vascular endothelial cell surface [49-136 
53]. Plexin receptors are well known to regulate GTPase activity via their intracellular GTPase 137 
activating-protein (GAP) domain [54], and recent studies demonstrated that binding of SEMA3E 138 
to PLXND1 in Human Umbilical Vein Endothelial Cells (HUVECs), inactivated the GTPase 139 
activity of R-Ras [14]. Work from the same lab further found that PLXND1 stimulated ARF6 140 
GTPase activity by local production of phosphatidylinositol 4,5-biphosphate (PI(4,5)P2) by type I 141 
phosphatidylinositol-4-phosphate-5-kinase (PIP5K) β [55]. Both of these pathways acted to 142 
modulate Integrin presentation on the HUVEC surface [56]. The role of Integrins has not been 143 
fully elucidated in AT [45, 57]. Further, the role of endothelial cell-localized Integrins on AT 144 
formation and growth appears essentially unstudied. However, based on the established 145 
mechanisms described above, we speculate that Integrin composition on the surface of VAT 146 
endothelial cells may play an important role in PlxnD1-mediated regulation of BFD.  147 
To test this hypothesis it will be necessary to manipulate the Integrin code on vascular 148 
endothelial cells and assess effects on ECM and VAT growth. Such experiments may be 149 
conducted by using the Tie2-CreTg (Tek-Cre) transgenic mouse line [58] to produce vascular 150 
endothelial cell-specific Integrin knockouts. Similar experiments have been performed previously 151 
to assess an endothelial cell-specific role for β1 Integrins [59-62]. As we hypothesize that β1 152 
Integrins mediate crosstalk between VAT endothelial cells and the ECM to regulate VAT growth 153 
[55], it will be essential to temporally control Cre-mediated recombination due to embryonic 154 
defects in β1 Integrin knockout mice by using inducible Cre lines [59]. Although the conditional 155 
knockout strategy described above allows the ablation of Integrins to be restricted to endothelial 156 
cells, and further controlled by using inducible Cre lines, it would also be desirable to restrict 157 
Integrin ablation to endothelial cells specifically within VAT. However, to our knowledge no such 158 
transgenic line currently exists that expresses solely in VAT endothelial cells. Therefore, such 159 
an experimental strategy will induce Integrin knockout in endothelial cells across the body, 160 
potentially leading to secondary effects on VAT growth. Molecular profiles of tissue-specific 161 
endothelial cells has been performed for a variety of tissue types [63], therefore a similar strategy 162 
in adipose tissues may yield adipose-specific endothelial cell profiles that may be utilized for 163 
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transgenic strategies. However, to circumvent secondary effects, endothelial cell and adipocyte 164 
co-cultures may also need to be performed [64, 65]. 165 
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Figure Legends 309 
Figure 1. Common variants and regulatory features at human PLXND1. Four tracks 310 
are depicted at the PLXND1 locus. In descending order: WHRadjBMI Variants; 49 variants linked 311 
to rs10804591 (European ancestry, 1000G Phase 1, >0.7 R2 in linkage disequilibrium of 312 
rs10804591). Genes; Havana annotated genes. Arrows within the first exon indicate direction of 313 
transcription. All Variants; common variants from 1000G Phase 1 with a frequency of at least 314 
1% within populations of European ancestry. Regulatory Features; regulation marks predicted 315 
by the Ensembl Regulatory Build [66]. Vertical black bars are 100 kb (A) or 10kb (B) apart. 316 
Brackets in A denote the region shown in B. 317 
 318 
Figure 2. β-coefficients and standard deviation for rs10804591. Bar charts indicate 319 
the β-coefficients and standard deviation (SD) for rs10804591 for waist-hip ratio adjusted for 320 
BMI (A; WHRadjBMI), waist circumference adjusted for BMI (WCadjBMI), and hip circumference 321 
adjusted for BMI (C, HIPadjBMI). All data are taken from Shungin et al. (2015). Asterisks indicate 322 
genome-wide significance (P < 5x10-8). Data are classified into 3 groups; sex-combined (black 323 
bars), female-only (white bars), and male-only (grey bars). Data are from GWAS or metabochip 324 
(MC) cohorts as described in Shungin et al. (2015). 325 
 326 
Figure 3. Fluorescent lipophilic dyes to study body fat distribution in zebrafish. Nile 327 
Red stained zebrafish demonstrating neutral lipid stored within ATs (labelled in yellow) at two 328 
developmental stages. The arrows indicate VAT. SL = standard length (a measure of the fish 329 
length from the snout to the caudal peduncle). 330 
 331 
Figure 4. Schematic illustrating the hypothesized mechanism by which vascular 332 
endothelial cell-derived Plxnd1 determines ECM composition and VAT expandability. A. 333 
Overview of the hyperproliferative and hyperplastic microenvironment of plxnd1 mutant zebrafish 334 
VAT. B. Schematic on the interaction between PlxnD1, Integrins and ECM composition. 335 
 336 
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